|
CD205, a target antigen for a novel antibody drug conjugate (ADC): Evaluation of antigen expression on non-Hodgkin lymphoma (NHL). |
|
|
Research Funding - Menarini (Inst) |
|
|
Research Funding - Menarini (Inst) |
|
|
Honoraria - CTI; Gilead Sciences; Janssen-Cilag; Menarini; Mundipharma; Roche; SERVIER; Takeda; Teva |
Consulting or Advisory Role - CTI; Gilead Sciences; Janssen-Cilag; Mundipharma; SERVIER |
Research Funding - Menarini (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Oxford BioTherapeutics |
Research Funding - Oxford BioTherapeutics |
Travel, Accommodations, Expenses - Oxford BioTherapeutics |
|
|
Employment - Oxford BioTherapeutics |
Stock and Other Ownership Interests - Bristol-Myers Squibb; Caladrius Biosciences; CytomX Therapeutics; Ensigna Biosystems; Genomic Health; Gilead Sciences; Sanofi |
Research Funding - Oxford BioTherapeutics |
Travel, Accommodations, Expenses - Leica Biosystems; Oxford BioTherapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
Employment - Oxford BioTherapeutics |
Research Funding - Oxford BioTherapeutics |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
No Relationships to Disclose |
|
Andrea Ugo Enrico Pellacani |
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
|